Sandoz receives FDA approval for first and only denosumab biosimilars – Morningstar

Giant Cell Tumor of Bone: Most common adverse reactions (≥ 10%) were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity.
Source: back pain